Compare First Trust Cloud Computing ETF (SKYY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs TG Therapeutics Inc — how do they compare? First Trust Cloud Computing ETF trades at $158.17, while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). Which is the better fit depends on your goals.
| SKYY | TGTX | |
|---|---|---|
52-Week High | $168.91 | $59.06 |
52-Week Low | $104.16 | $26.94 |
Market Cap | — | $8.53B |
Sector | — | Health |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY, the First Trust Cloud Computing ETF, trades at $159.62, down 1.2% on the day. Technical indicators show a neutral to bullish bias, with moving averages bullish and oscillators neutral. Recent news highlights strong AI-driven demand for cloud infrastructure, positioning SKYY to benefit from secular trends in cloud migration and data center investments.
The outlook for SKYY is positive, driven by AI adoption and cloud spending growth, but risks include market volatility and sector competition. Analyst sentiment is supportive, with the ETF offering diversified exposure without heavy concentration in mega-cap tech stocks.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
